[1] |
WANG Ting, QIN Yi, XU Xiaowu, YU Xianjun.
New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024
[J]. China Oncology, 2025, 35(1): 1-11.
|
[2] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[3] |
WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi.
Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model
[J]. China Oncology, 2024, 34(9): 873-880.
|
[4] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
[5] |
CHEN Hong, CAO Zhiyun.
Recent progress in the construction and application of patient-derived pancreatic cancer organoid models
[J]. China Oncology, 2024, 34(6): 590-597.
|
[6] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
[7] |
REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng.
An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
[J]. China Oncology, 2024, 34(12): 1090-1099.
|
[8] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|
[9] |
TAN Xiaolang, YAO Sha, WANG Guihua, PENG Luogen.
Research on uPAR promoting proliferation, migration, and chemoresistance of pancreatic cancer by inhibiting autophagy via MAPK signaling
[J]. China Oncology, 2024, 34(10): 944-956.
|
[10] |
LI Tianjiao, YE Longyun, JIN Kaizhou, WU Weiding, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023
[J]. China Oncology, 2024, 34(1): 1-12.
|
[11] |
JIN Yizi, LIN Mingxi, ZHANG Jian.
Receptor discordance between primary breast cancer and liver metastases
[J]. China Oncology, 2023, 33(9): 834-843.
|
[12] |
WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong.
The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer
[J]. China Oncology, 2023, 33(9): 844-856.
|
[13] |
CHEN Jinjuan, WANG Xingran, LI Wenzhi, CHENG Yu, SUN Yihua, TAO Xiang, MA Fenghua, SUN Li, ZHAO Hongbo, LU Xin.
Conservative surgery in stage I placental site trophoblastic tumor: a report of 10 cases and literature review
[J]. China Oncology, 2023, 33(9): 857-865.
|
[14] |
SUN Yang, WANG Lian, ZHAO Meng, ZHANG Xiaofeng, GENG Zhijun, WANG Yueyue, SONG Xue, ZUO Lugen, LI Jing, HU Jianguo.
The prognostic value of high expression of FKBP1A in gastric cancer and the regulatory effect of targeted PI3K/AKT on glucose metabolism
[J]. China Oncology, 2023, 33(8): 726-739.
|
[15] |
JIANG Lin, LIU Qiying, JIA Liqing, ZHANG Jing, CHANG Heng, XUE Tian, REN Min, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan.
Retrospective study on MGMT methylation status and its clinical significance in gliomas
[J]. China Oncology, 2023, 33(8): 740-750.
|